...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres II. In vitro investigation
【24h】

Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres II. In vitro investigation

机译:通过调节其从卵清蛋白微球II的物理化学修饰基质中释放,可增强辅助品对二甲基二肽的辅助作用。体外调查

获取原文
获取原文并翻译 | 示例
           

摘要

In the present study, sustaining the release of adjuvants was investigated using microspheres as a means to increase the immune response (i.e. efficacy) and, ultimately, to reduce adverse effects to vaccine components. To date, most attempts have focused on sustaining the release of antigens. The utility of currently used vaccine adjuvants may be improved by sustaining their release. The development, modification and characterization of a two-component microsphere vaccine delivery system was demonstrated in our previous report [Puri et al., J. Control. Release (2000) in press]. Briefly, ovalbumin (OVA) was utilized as the model antigen (Ag) and delivery matrix and MDP or threonyl-MDP served as the model adjuvants. The release pattern of MDP was modulated from a physicochemically modified matrix of OVA microspheres (OVA-MSs). The purpose of the present study was to evaluate the adjuvancy of MDP in mice by modulating its release from OVA-MSs. Mice were immunized intradermally (i.d.) with various preparations of OVA-MSs, using a single-shot-immunization technique. Positive and negative control preparations were evaluated as well. An inverse relationship was observed between the in vitro release rate of MDP and the in vivo OVA-specific IgG antibody (Ab) immune response in mice. These results demonstrated that modulating the release pattern of MDP or threonyl-MDP enhanced their adjuvant effect. In conclusion, the current results demonstrate that the sustained and controlled release of adjuvants is extremely important for inducing a high level and prolonged period of immunostimulation while potentially minimizing therapy-limiting adverse effects. (C) 2000 Elsevier Science B.V. All rights reserved. [References: 23]
机译:在本研究中,使用微球作为增加免疫反应(即功效)并最终减少对疫苗成分的不良影响的手段,研究了维持佐剂释放的方法。迄今为止,大多数尝试都集中在维持抗原的释放上。当前使用的疫苗佐剂的实用性可以通过维持其释放来提高。我们先前的报告[Puri等人,J。Control。发行中(2000年)]。简而言之,卵清蛋白(OVA)被用作模型抗原(Ag)和递送基质,而MDP或苏糖基MDP用作模型佐剂。 MDP的释放模式是通过OVA微球(OVA-MS)的物理化学修饰的基质来调节的。本研究的目的是通过调节MDP从OVA-MS的释放来评估其在小鼠中的辅助作用。使用单次免疫技术,用各种OVA-MS制剂对小鼠进行皮内(i.d.)免疫。阳性和阴性对照制剂也进行了评估。在小鼠中,MDP的体外释放速率与体内OVA特异性IgG抗体(Ab)免疫反应之间存在反比关系。这些结果表明,调节MDP或苏糖基-MDP的释放模式可增强其佐剂作用。总之,当前的结果表明,佐剂的持续和控制释放对于诱导高水平和延长的免疫刺激时间同时潜在地最小化治疗限制的不良反应极为重要。 (C)2000 Elsevier Science B.V.保留所有权利。 [参考:23]

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号